- |||||||||| nezastomig (REGN5678) / Regeneron, Libtayo (cemiplimab-rwlc) / Regeneron, REGN4336 / Regeneron
Enrollment change, Trial completion date, Trial primary completion date, Combination therapy, Metastases: A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer (clinicaltrials.gov) - Feb 15, 2024 P1/2, N=370, Recruiting, N=199 --> 370 | Trial completion date: Aug 2026 --> Jan 2027 | Trial primary completion date: Aug 2026 --> Jan 2027
|